Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636327 | 0.98 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2SRCERN1 | |
| SCHEMBL636533 | 0.94 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2SRCERN1 | |
| SCHEMBL1242931 | 0.91 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2SRCALDH1A1 | |
| SCHEMBL28004812 | 0.91 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2SRCALDH1A1 | |
| SCHEMBL11439257 | 0.91 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2SRCALDH1A1 | |
| SCHEMBL637742 | 0.91 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2SRCERN1 | |
| SCHEMBL31612271 | 0.88 | ALDH1A1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL31612273 | 0.88 | ALDH1A1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL637615 | 0.85 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2SRCERN1 | |
| SCHEMBL7775011 | 0.85 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2SRCERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| EP-2229388-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009109987-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | TRPV3, TRPV1, TRPV5 | NPC1 1398/4885RAB9A 1584/4885SMN1; SMN2 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.